登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《MedRxiv，4月15日，（第3版更新）The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-16

  • The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective clinical study

    CHEN SHI, CONG WANG, HANXIANG WANG, CHAO YANG, FEI CAI, FANG ZENG, FANG CHENG, YIHUI LIU, TAOTAO ZHOU, BIN DENG, Israel Vlodavsky, JINPING LI, YU ZHANG

    doi: https://doi.org/10.1101/2020.03.28.20046144

    Abstract

    Background On March 11, 2020, the World Health Organization declared its assessment of COVID-19 as a global pandemic. However, specific antiviral drugs are still unavailable, and pateints are managed by multiple complementary treatments. Methods The electronic medical records of COVID-19 patients where basic information, complete blood count, coagulation profile, inflammatory cytokines and serum biochemical indicators in 42 patients with COVID-19 (21 of whom were treated with low molecular weight heparin (LMWH), and 21 without LMWH) that were retrospectively analyzed to compare and evaluate the effect of LMWH treatment on disease progression. Findings 42 patients with COVID-19 treated at the hospital between February 1 and March 15, 2020, were selected for the study, of which 21 underwent LMWH treatment (LMWH group), and 21 did not (Control), during hospitalization. Changes in the percentage of lymphocytes in the LMWH group before and after LMWH treatment were significantly different from those in the control group (p=0.011, respectively).

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.medrxiv.org/content/10.1101/2020.03.28.20046144v3
40浏览量
原文链接
相关报告

  • 《MedRxiv，4月20日，（第2版更新）Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: A multicenter retrospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-21
    • Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: A multicenter retrospective cohort study Ziyun Shao Sr., Yongwen Feng, Li Zhong, Qifeng Xie, Ming Lei, Zheying Liu, Conglin Wang, Jingjing Ji, Huiheng Liu, Zhengtao Gu, Zhongwei Hu, Lei Su, Min Wu, Zhifeng Liu doi: https://doi.org/10.1101/2020.04.11.20061739 Abstract Importance: Coronavirus disease 2019 (COVID-19) has become pandemic, causing more than 1.5 million infections and over ten-thousands of deaths in a short period of time worldwide. However, little is known about its pathological mechanism, and reports on clinical study on specific treatment are few. Objective: The purpose of this study is to determine the clinical efficacy of intravenous immunoglobulin (IVIG) therapy in COVID-19 patients. Design, setting and participants: This multicenter retrospective cohort study enrolled 325 adult critical COVID-19 patients, including severe type and critical type, according to the clinical classification defined by National Health Commission of China, in 8 government designated treatment centers in China from Dec 23, 2019 to Mar 31, 2020. Demographic, clinical, treatment, and laboratory data as well as prognosis were extracted from electronic medical records. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    101浏览量
    原文链接

  • 《Lancet，6月24日，Tocilizumab in patients with severe COVID-19: a retrospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-26
    • Tocilizumab in patients with severe COVID-19: a retrospective cohort study Prof Giovanni Guaraldi, MD † Marianna Meschiari, MD † Prof Alessandro Cozzi-Lepri, PhD Jovana Milic, MD Roberto Tonelli, MD Marianna Menozzi, MD Published:June 24, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30173-9 Summary Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment. Methods This retrospective, observational cohort study included adults (≥18 years) with severe COVID-19 pneumonia who were admitted to tertiary care centres in Bologna and Reggio Emilia, Italy, between Feb 21 and March 24, 2020, and a tertiary care centre in Modena, Italy, between Feb 21 and April 30, 2020. All patients were treated with the standard of care (ie, supplemental oxygen, hydroxychloroquine, azithromycin, antiretrovirals, and low molecular weight heparin), and a non-randomly selected subset of patients also received tocilizumab. Tocilizumab was given either intravenously at 8 mg/kg bodyweight (up to a maximum of 800 mg) in two infusions, 12 h apart, or subcutaneously at 162 mg administered in two simultaneous doses, one in each thigh (ie, 324 mg in total), when the intravenous formulation was unavailable.
    168浏览量
    原文链接